Characterization of the Cytochrome P450 epoxyeicosanoid pathway in non-alcoholic steatohepatitis

Chalasani, 2012, The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association, Hepatology, 55, 2005, 10.1002/hep.25762 Rinella, 2015, Nonalcoholic fatty liver disease: a systematic review, JAMA, 313, 2263, 10.1001/jama.2015.5370 Zeldin, 2001, Epoxygenase pathways of arachidonic acid metabolism, J. Biol. Chem., 276, 36059, 10.1074/jbc.R100030200 Imig, 2012, Epoxides and soluble epoxide hydrolase in cardiovascular physiology, Physiol. Rev., 92, 101, 10.1152/physrev.00021.2011 Deng, 2010, Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation, J. Mol. Cell. Cardiol., 48, 331, 10.1016/j.yjmcc.2009.10.022 Oni-Orisan, 2014, Epoxyeicosatrienoic acids and cardioprotection: the road to translation, J. Mol. Cell. Cardiol., 74, 199, 10.1016/j.yjmcc.2014.05.016 Luria, 2011, Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance, Proc. Natl. Acad. Sci. U. S. A., 108, 9038, 10.1073/pnas.1103482108 Liu, 2012, Inhibition of soluble epoxide hydrolase attenuates high-fat-diet-induced hepatic steatosis by reduced systemic inflammatory status in mice, PLoS One, 7, e39165, 10.1371/journal.pone.0039165 Sodhi, 2012, EET agonist prevents adiposity and vascular dysfunction in rats fed a high fat diet via a decrease in Bach 1 and an increase in HO-1 levels, Prostaglandins Other Lipid Mediat., 98, 133, 10.1016/j.prostaglandins.2011.12.004 Bettaieb, 2013, Soluble epoxide hydrolase deficiency or inhibition attenuates diet-induced endoplasmic reticulum stress in liver and adipose tissue, J. Biol. Chem., 288, 14189, 10.1074/jbc.M113.458414 Zha, 2014, Functional characterization of cytochrome P450-derived epoxyeicosatrienoic acids in adipogenesis and obesity, J. Lipid Res., 55, 2124, 10.1194/jlr.M053199 Schuck, 2014, The cytochrome P450 epoxygenase pathway regulates the hepatic inflammatory response in fatty liver disease, PLoS One, 9, e110162, 10.1371/journal.pone.0110162 Loomba, 2015, Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis, J. Lipid Res., 56, 185, 10.1194/jlr.P055640 Sinal, 2000, Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation, J. Biol. Chem., 275, 40504, 10.1074/jbc.M008106200 Deng, 2011, Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice, FASEB J., 25, 703, 10.1096/fj.10-171488 Takahashi, 2012, Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis, World J. Gastroenterol., 18, 2300, 10.3748/wjg.v18.i19.2300 Larter, 2008, Animal models of NASH: getting both pathology and metabolic context right, J. Gastroenterol. Hepatol., 23, 1635, 10.1111/j.1440-1746.2008.05543.x Ferslew, 2015, Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis, Clin. Pharmacol. Ther., 97, 419, 10.1002/cpt.66 Ferslew, 2015, Altered bile acid metabolome in patients with nonalcoholic steatohepatitis, Dig. Dis. Sci., 60, 3318, 10.1007/s10620-015-3776-8 Oni-Orisan, 2016, Cytochrome P450-derived epoxyeicosatrienoic acids and coronary artery disease in humans: a targeted metabolomics study, J. Lipid Res., 57, 109, 10.1194/jlr.M061697 Theken, 2011, Activation of the acute inflammatory response alters cytochrome P450 expression and eicosanoid metabolism, Drug Metab. Dispos., 39, 22, 10.1124/dmd.110.035287 Szabo, 2013, MicroRNAs in liver disease, Nat. Rev. Gastroenterol. Hepatol., 10, 542, 10.1038/nrgastro.2013.87 Clarke, 2014, Circulating microRNA 122 in the methionine and choline-deficient mouse model of non-alcoholic steatohepatitis, J. Appl. Toxicol., 34, 726, 10.1002/jat.2960 Church, 2016, Beyond miR-122: identification of microRNA alterations in blood during a time course of hepatobiliary injury and biliary hyperplasia in rats, Toxicol. Sci., 150, 3, 10.1093/toxsci/kfv260 Kroh, 2010, Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR), Methods, 50, 298, 10.1016/j.ymeth.2010.01.032 Mehlem, 2013, Imaging of neutral lipids by oil red O for analyzing the metabolic status in health and disease, Nat. Protoc., 8, 1149, 10.1038/nprot.2013.055 Sampey, 2011, Cafeteria diet is a robust model of human metabolic syndrome with liver and adipose inflammation: comparison to high-fat diet, Obesity, 19, 1109, 10.1038/oby.2011.18 Pettersson, 2012, Female mice are protected against high-fat diet induced metabolic syndrome and increase the regulatory T cell population in adipose tissue, PLoS One, 7, e46057, 10.1371/journal.pone.0046057 Xia, 2012, Metabo Analyst 2.0 – a comprehensive server for metabolomic data analysis, Nucleic Acids Res., 40, W127, 10.1093/nar/gks374 Maric-Bilkan, 2016, Report of the National Heart, Lung, and Blood Institute working group on sex differences research in cardiovascular disease: scientific questions and challenges, Hypertension, 67, 802, 10.1161/HYPERTENSIONAHA.115.06967 Shearer, 2009, Impact of circulating esterified eicosanoids and other oxylipins on endothelial function, Curr. Atheroscler. Rep., 11, 403, 10.1007/s11883-009-0061-3 Morgan, 2001, Regulation of cytochrome p450 by inflammatory mediators: why and how?, Drug Metab. Dispos., 29, 207 Theken, 2012, Enalapril reverses high-fat diet-induced alterations in cytochrome P450-mediated eicosanoid metabolism, Am. J. Physiol. Endocrinol. Metab., 302, E500, 10.1152/ajpendo.00370.2011 Spector, 2004, Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function, Prog. Lipid Res., 43, 55, 10.1016/S0163-7827(03)00049-3 Yu, 2007, Lipoprotein lipase activator ameliorates the severity of dietary steatohepatitis, Biochem. Biophys. Res. Commun., 356, 53, 10.1016/j.bbrc.2007.02.129 Puri, 2009, The plasma lipidomic signature of nonalcoholic steatohepatitis, Hepatology, 50, 1827, 10.1002/hep.23229 Feldstein, 2010, Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, J. Lipid Res., 51, 3046, 10.1194/jlr.M007096 Hoopes, 2015, Vascular actions of 20-HETE, Prostaglandins Other Lipid Mediat., 120, 9, 10.1016/j.prostaglandins.2015.03.002 Node, 1999, Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids, Science, 285, 1276, 10.1126/science.285.5431.1276 Hye Khan, 2013, Orally active epoxyeicosatrienoic acid analog attenuates kidney injury in hypertensive Dahl salt-sensitive rat, Hypertension, 62, 905, 10.1161/HYPERTENSIONAHA.113.01949 Manhiani, 2009, Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension, Am. J. Physiol. Renal Physiol., 297, F740, 10.1152/ajprenal.00098.2009 Sirish, 2013, Unique mechanistic insights into the beneficial effects of soluble epoxide hydrolase inhibitors in the prevention of cardiac fibrosis, Proc. Natl. Acad. Sci. U. S. A., 110, 5618, 10.1073/pnas.1221972110 Zhang, 2008, Soluble epoxide hydrolase gene deletion is protective against experimental cerebral ischemia, Stroke, 39, 2073, 10.1161/STROKEAHA.107.508325 Liu, 2012, Attenuation of cisplatin-induced renal injury by inhibition of soluble epoxide hydrolase involves nuclear factor kappaB signaling, J. Pharmacol. Exp. Ther., 341, 725, 10.1124/jpet.111.191247 Harris, 2015, Inhibition of soluble epoxide hydrolase attenuates hepatic fibrosis and endoplasmic reticulum stress induced by carbon tetrachloride in mice, Toxicol. Appl. Pharmacol., 286, 102, 10.1016/j.taap.2015.03.022 Johnson, 2012, The inflammation highway: metabolism accelerates inflammatory traffic in obesity, Immunol. Rev., 249, 218, 10.1111/j.1600-065X.2012.01151.x Odegaard, 2013, Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis, Science, 339, 172, 10.1126/science.1230721 Weisberg, 2006, CCR2 modulates inflammatory and metabolic effects of high-fat feeding, J. Clin. Invest., 116, 115, 10.1172/JCI24335 Imig, 2009, Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases, Nat. Rev. Drug Discov., 8, 794, 10.1038/nrd2875 Shen, 2012, Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications, J. Med. Chem., 55, 1789, 10.1021/jm201468j Lazaar, 2016, Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor, Br. J. Clin. Pharmacol., 81, 971, 10.1111/bcp.12855